Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
FEMS Immunol Med Microbiol ; 44(3): 269-76, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15907448

ABSTRACT

In the present study, we evaluated the immunopotentiating efficacy of tuftsin against experimental murine aspergillosis in both normal and immunodebilitant BALB/c mice. The animals were challenged with an isolate of Aspergillus fumigatus (1x10(8) cfu/mouse) that was showing less susceptibility to lower doses of amphotericin B in murine animal model. Co-administration of the immunomodulator tuftsin and liposomised-amphotericin B was found to be highly effective in the treatment of systemic infection of A. fumigatus in both immunocompetent and leukopenic mice. Moreover, pre-treatment of mice with liposomised-tuftsin prior to challenging them with A. fumigatus infection and subsequent treatment with tuftsin-bearing liposomised-amphotericin B was found to be extremely efficient in successful elimination of fungal pathogen. In another set of experiments, tuftsin-mediated antigen-specific memory antibody response was also assessed by immunizing the animals with A. fumigatus cytosolic antigen. The animals that received a booster 150 days after the first immunization with tuftsin-liposomes-antigen showed more resistance to A. fumigatus infection in comparison with the naïve animals.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Aspergillosis/immunology , Aspergillosis/prevention & control , Aspergillus fumigatus , Immunologic Factors/therapeutic use , Tuftsin/therapeutic use , Amphotericin B/pharmacology , Animals , Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Drug Evaluation, Preclinical , Drug Therapy, Combination , Immunocompromised Host , Immunologic Factors/pharmacology , Liposomes , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests
2.
FEMS Immunol Med Microbiol ; 41(3): 249-58, 2004 Jul 01.
Article in English | MEDLINE | ID: mdl-15196575

ABSTRACT

In order to develop a prospective chemotherapeutic agent against opportunistic infections, it is important to know that host factors such as degree of immunological debility as well as recovery of immune functions to normality may contribute significantly to a successful elimination of the pathogens. We demonstrated previously that concomitant delivery of antimicrobial agents and immunomodulators to the pathogen harbouring-host contributes to the complete elimination of the deep-seated fungal infections (aspergillosis and candidiasis) in animals with normal immune status. Considering that neutropenic hosts are the main targets of such infections, it can be argued about the potential of the immunomodulator-based therapy in subjects with non-functional immune system. To resolve the hypothesis, we studied the role of immunomodulator tuftsin against experimental murine candidiasis in temporarily neutropenic Balb/c mice. The neutropenic mice were challenged with an isolate of Candida albicans that was showing less susceptibility to both free and liposomised-amphotericin B. The co-administration of tuftsin increased the efficiency of liposomised-polyene antibiotics (nystatin and amphotericin B) against experimental murine candidiasis in immunocompromised Balb/c mice. Pretreatment with liposomised tuftsin prior to C. albicans infection clearly enhanced protection against candidiasis, suggesting a prophylactic role of tuftsin in normal and temporarily neutropenic animals.


Subject(s)
Antifungal Agents/administration & dosage , Candida albicans , Candidiasis/drug therapy , Liposomes/administration & dosage , Neutropenia/complications , Nystatin/administration & dosage , Tuftsin/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Candida albicans/pathogenicity , Candidiasis/immunology , Candidiasis/microbiology , Candidiasis/prevention & control , Drug Synergism , Drug Therapy, Combination , Female , Mice , Mice, Inbred BALB C , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...